First-in-class asthma treatment gets provisional green light
The National Institute for Health and Care Excellence (NICE) has given its provisional backing to a new type of treatment for adults with severe asthma.

Mepolizumab (Nucala) is the first biological treatment to target eosinophils, the inflammatory cells which are responsible for symptoms in thousands of asthma patients.

It will be an extra option for people with the most severe symptoms, including those who suffer multiple asthma attacks, says NICE....

http://www.onmedica.com/newsArticle.aspx?id=76a30882-a30d-4fe4-a735-ca7d077f0fd5
Like
Comment
Share